en
Scientific article
English

Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis

Published inSchweizerische medizinische Wochenschrift, vol. 142, w13536
Publication date2012
Abstract

Anticoagulation therapy is routinely used in cases of non ST-segment elevation acute coronary syndromes (NSTE-ACS). The most commonly used drug in such events is enoxaparin, a low molecular weight heparin. Fondaparinux, a synthetic pentasaccharide, is as effective as enoxaparin in terms of survival or residual angina pectoris and significantly reduces bleeding complications. The purpose of this study was to assess the magnitude of cost reductions if enoxaparin were replaced by fondaparinux in Switzerland.

Keywords
  • Acute Coronary Syndrome/drug therapy/economics
  • Aged
  • Anticoagulants/economics/therapeutic use
  • Costs and Cost Analysis
  • Drug Costs/statistics & numerical data
  • Enoxaparin/economics/therapeutic use
  • Factor X
  • Female
  • Follow-Up Studies
  • Hospital Costs/statistics & numerical data
  • Humans
  • Length of Stay/economics
  • Male
  • Polysaccharides/economics/therapeutic use
  • Retrospective Studies
  • Switzerland
  • Treatment Outcome
Citation (ISO format)
KOSSOVSKY, Michel et al. Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis. In: Schweizerische medizinische Wochenschrift, 2012, vol. 142, p. w13536. doi: 10.4414/smw.2012.13536
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0036-7672
444views
0downloads

Technical informations

Creation11/13/2013 8:20:00 AM
First validation11/13/2013 8:20:00 AM
Update time03/14/2023 8:41:30 PM
Status update03/14/2023 8:41:30 PM
Last indexation01/16/2024 8:25:14 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack